FDA-approved Skin & aging

Icatibant

Icatibant is a bradykinin B2 antagonist. It is filed in this library under skin & aging, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Icatibant has an FDA-approved product on the U.S. market, marketed as Sajazir under application ANDA212446.

The current label is held by Cycle Pharmaceuticals Ltd-Uk.

From the FDA label

What Icatibant is approved to treat

(icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Icatibant, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on skin & aging

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Icatibant. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides